Investigator’s brochure

An investigator’s brochure is a key document outlining the scientific narrative, the safety positioning and other key details to ensure clear communication of the project. 

A strong, clear and consistent investigator’s brochure is key for reducing regulatory and development risk.

Talk to an expert
Contact our consultants

When investigator’s brochure support becomes critical

Sponsors most often engage investigator’s brochure (IB) support at moments where pressure, complexity, or uncertainty increase. This typically happens when the IB shifts from being a formal requirement to becoming an active reference point for decisions, safety reporting, and regulatory interactions. The situations typically involve the following types of development changes.

The IB is never a static document and serves as the backbone of your project and as a communication and risk management tool.

Preparing a first investigator’s brochure to enable a first-in-human study

Integrating new non-clinical or clinical data that materially changes the safety profile

Repositioning the programme after a change in indication, dosing rationale, or development strategy

Responding to authority questions, inspection feedback, or increased scrutiny

klifo_miljø-075

What KLIFO delivers

KLIFO takes end-to-end responsibility for investigator’s brochure preparation, updates, and lifecycle management.

Our role is to ensure that the IB remains scientifically sound, internally consistent, and regulatorily defensible as the programme evolves. This includes:

  • Preparation of first-time investigator’s brochure
  • Strategic revisions following new pharmacology, toxicology, or clinical data
  • Integration of clinical, non-clinical, CMC, and regulatory inputs into one coherent narrative
  • Alignment with related regulatory documentation and safety reporting frameworks
  • Controlled updates and version governance across development phases

We do not simply compile information. We assess relevance, identify inconsistencies, challenge assumptions, and ensure that conclusions are supported by the totality of available data.

The result is an investigator’s brochure that supports safe trial conduct and stands up to detailed regulatory review.

Klifo, Glostrup. 07/10-2025

Regulatory context without unnecessary friction

Investigator’s brochures must meet expectations under Good Clinical Practice and applicable international guidance, including ICH E6 and the Clinical Trial Regulation in Europe.

KLIFO’s role is to translate regulatory intent into practical execution. We ensure that safety positioning is clear, conclusions are traceable, and updates are controlled and justifiable during authority interactions or inspections.

Sponsors remain accountable for the investigator’s brochure. Our contribution is to ensure that accountability is supported by experienced judgement and robust delivery.

Why investigator’s brochures fail in practice

Many investigator’s brochures meet formal requirements yet still create downstream issues.

These issues rarely stem from missing data. They stem from insufficient cross-functional alignment and lack of senior oversight.

KLIFO’s multidisciplinary setup is designed to prevent exactly this. By working across Drug Development and Regulatory Affairs, we ensure that the investigator’s brochure reflects a unified, current view of the programme at all times.

Inconsistencies between non-clinical and clinical sections

Safety conclusions that lag behind emerging data

Misalignment between CMC deliverables and clinical needs described in the Target Product Profile

Mechanical updates without strategic reassessment of the overall story

Klifo, Glostrup. 07/10-2025

Where the investigator’s brochure fits

The investigator’s brochure supports all phases of clinical development. Its role expands as programmes progress, but its importance remains constant.

It enables study initiation, anchors safety expectedness, supports authority dialogue, and maintains consistency across evolving submissions. When handled well, it rarely draws attention. When it is not, it often becomes a bottleneck.

Our role is to keep it in the first category.

Klifo, Glostrup. 07/10-2025

investigator’s brochure

Ready to move forward?

An investigator’s brochure does not need to be impressive.
It needs to be right, consistent, and defensible.

That is where KLIFO adds value.

Let’s talk